readthroughSign in
Nov 16, 2026Weekly roundup3 fact check notes

Novo Nordisk posts results for Phase 3 dasiglucagon and liraglutide pediatric trials

Novo Nordisk logged new results postings for two Phase 3 studies on November 16, 2026, and a Zealand University Hospital study backed by the Novo Nordisk Foundation was registered.

Novo Nordisk had a quiet week for new registrations but posted results for two existing Phase 3 programs and saw a foundation-funded observational study added to the registry.

  • The Phase 3 trial titled "A Phase 3, Randomised, Open-label, Cross-over Study to Confirm the Clinical Efficacy and Safety of Dasiglucagon Versus Glucagon for the Treatment of Severe Hypoglycaemia in Asian Adults With Type 1 Diabetes (T1D) Including an Investigation of Dasiglucagon in a Japanese Adolescent Cohort" (NCT06588504) is listed as completed, with primary completion and study completion both recorded as July 20, 20251, and results were first posted November 16, 2026. The study enrolled 38 participants in a randomized, open-label crossover design1, comparing dasiglucagon to glucagon for treating severe hypoglycemia in Asian adults with type 1 diabetes, with an added cohort testing dasiglucagon in Japanese adolescents.
  • Primary completion occurred on August 1, 2023, while study completion is estimated for February 8, 20272, and results for the trial were first posted November 16, 2026. The study randomized 82 participants to liraglutide 3.0 mg or placebo2, with the primary outcome measuring relative change in BMI from baseline to week 562.
  • A new observational study, "The Proteome of Chronic Urticaria" (NCT07940491), was registered with a status of not yet recruiting and an estimated start of December 2026. The study is sponsored by Zealand University Hospital, with Novo Nordisk Foundation listed as a collaborator3. Researchers plan to analyze skin biopsies from chronic urticaria patients using mass spectrometry-based proteomics3, with an estimated enrollment of 80 participants3.

Fact check notes

  • ImpreciseNovo Nordisk posts results for Phase 3 dasiglucagon and liraglutide pediatric trialsThe headline calls the dasiglucagon study a "pediatric trial," but per the source it is primarily an adult trial (ages 18-75, 33 of 38 participants adults) with only a small added Japanese adolescent cohort (4 participants aged 12-15). Only the liraglutide study is truly pediatric.
  • Checker's noteHeadline/summary frames the dasiglucagon study as a 'pediatric' trial, but it is predominantly an adult trial (ages 18-75) with only a small (4-participant) Japanese adolescent sub-cohort, so labeling it alongside the liraglutide pediatric trial as a pair of 'pediatric trials' overstates and mischaracterizes the dasiglucagon study's scope.
  • Sentence removedThe Phase 3 trial "Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial" (NCT04775082), known as SCALE KIDS, is listed as active, not recruiting.a figure with no citation

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.